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Abstract
Background: ZK 200775 is an antagonist at the a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and
had earned attention as a possible neuroprotective agent in cerebral ischemia. Probands receiving the agent within phase I
trials reported on an alteration of visual perception. In this trial, the effects of ZK 200775 on the visual system were analyzed
in detail.
Methodology: In a randomised controlled trial we examined eyes and vision before and after the intravenous
administration of two different doses of ZK 200775 and placebo. There were 3 groups of 6 probands each: Group 1 recieved
0.03 mg/kg/h, group 2 0.75 mg/kg/h of ZK 200775, the control group received 0.9% sodium chloride solution. Probands
were healthy males aged between 57 and 69 years. The following methods were applied: clinical examination, visual acuity,
ophthalmoscopy, colour vision, rod absolute threshold, central visual field, pattern-reversal visual evoked potentials (pVEP),
ON-OFF and full-field electroretinogram (ERG).
Principal Findings: No effect of ZK 200775 was seen on eye position or motility, stereopsis, pupillary function or central
visual field testing. Visual acuity and dark vision deteriorated significantly in both treated groups. Color vision was most
remarkably impaired. The dark-adapted ERG revealed a reduction of oscillatory potentials (OP) and partly of the a- and b-
wave, furthermore an alteration of b-wave morphology and an insignificantly elevated b/a-ratio. Cone-ERG modalities
showed decreased amplitudes and delayed implicit times. In the ON-OFF ERG the ON-answer amplitudes increased whereas
the peak times of the OFF-answer were reduced. The pattern VEP exhibited lower amplitudes and prolonged peak times.
Conclusions: The AMPA receptor blockade led to a strong impairment of typical OFF-pathway functions like color vision
and the cone ERG. On the other hand the ON-pathway as measured by dark vision and the scotopic ERG was affected as
well. This further elucidates the interdependence of both pathways.
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Glutamate is an important excitatory neurotransmitter of the
retina [1,2,3]. Besides neuronal excitation it also participates in
neuronal development, synaptic plasticity and neurotoxicity
(excitoxicity) [4,5,6,7]. Its activity is mediated by metabotropic
and ionotropic glutamate receptors (mGluRs and iGluRs). The
latter are subdivided into N-methyl-D-aspartate (NMDA) and
non-NMDA receptors. The latter again are classified as a-Amino-
3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA, composed of
the subunits iGluR1-4) and kainate (composed of the subunits
iGluR6-7) receptors (see Figure S1).
Non-NMDA receptors predominate in the retinal OFF-
pathway of the mammalian retina. In animal experiments, AMPA
receptor subunits have been localized in the inner and outer
plexiforme layer, in amacrine, bipolar and horizontal cells as well
as in ganglion cells and Muller glial cells [8,9,10,11]. Webvision
gives a survey of published data in different species (see Table S1)
[12].
ZK 200775 was developed by Schering AG (Berlin, Germany)
as an antagonist at the AMPA receptor. It raised expectations as a
possible neuroprotective agent in cerebral ischemia. The data
presented here was obtained in the resarch phase I to evaluate the
safety, tolerability and pharmacokinetics of the drug [13,14,15]. In
earlier trial, probands receiving ZK 200775 claimed to have
blurred vision and a strongly impaired color perception so the aim
of this investigation was to quantifiy the ophthalmologic effects of
ZK200775 by adequate examinations.
In the meanwhile, further development of the drug has been
aborted because of intolerable, but vision unrelated adverse
reactions [16,17,18].
On a microscopic level, distribution and physiology of retinal
AMPA receptors have been studied exhaustively. The advent of a
phase I trial of ZK200775 opened the unique opportunity to
investigate the effects of a receptor blockade in vivo, i.e. to
elucidate the function of AMPA receptors on visual perception in
humans.
Results
The administration of ZK 200775 had no effect on eye position
(Table S2) and motility (Table S3), stereopsis as tested with the
Titmus test, pupillary afference and efference (Table S4), central
visual field testing with the Amsler grid (Table S5) and anterior
and posterior segment morphology.
Visual acuity
Visual acuity deteriorated significantly in both verum groups
post-treatment (p=0.038 in group 1 and p=0.004 in group 2).
After 22 hours the baseline level was almost restored. The right eye
was not tested as the pupil was dilated. See Figure 1 and Table 1.
Color Vision
The most pronounced effect of ZK 200775 was seen on color
vision as estimated with the desaturated Lanthony Panel D-15 test.
The differences between the baseline and post-treatment error
scores were significant for both treated groups being 22.16 and
39.15 in group 1 and 2, respectively, but only 0.17 in the control
group. After 22 hours error scores of the treated groups returned
to the baseline level (Figure 2 and Table 2).
Dark vision
Likewise, dark vision was impaired after drug administration. A
significant elevation of the absolute rod threshold could be observed
in both treated groups at 4 hours (p=0.002 for both groups) and in
group 2 even at 22 hours (p=0.026). Figure 3 and Table 3 show
that the deteriorationofdarkvisionwasdose-dependent andthatno
impairment was observed in the control group.
ZK 200775 administration exerted various effects on the
electrophysiologic recordings. In the statistic calculation we
included amplitudes and peak times as measured in the single
recordings. The mean values that can be read out of the diagrams
(Figure 4, 5, 6, and 7) may differ from the mean values calculated
from the single recordings. We hold that in case of ambiguous
results the summed up responses as seen in the mentioned
diagrams most clearly demonstrate the effects of the drug on
electrophysiology.
Scotopic Electroretinogram (ERG)
There was a small but obvious difference of the b-wave
morphology before and after drug administration (Figure 4,
Figure 1. Visual acuity. Time course of mean values +/2 2 * standard
deviation for 6 subjects of each group. A significant deterioration
compared to baseline was observed in both verum groups 4 hours after
treatment (asterisked bars). As the pupil of the right eye was dilated
acuity testing was only performed in the left eye.
doi:10.1371/journal.pone.0012111.g001
Table 1. Visual acuity.
Group Comparison P-value
Low dose (Group 1) +4 hours vs. baseline 0.038*
+22 hours vs. baseline 0.363
High dose (Group 2) +4 hours vs. baseline 0.004*
+22 hours vs. baseline 0.518
Control group +4 hours vs. baseline 0.363
+22 hours vs. baseline 0.363
P-Values for the comparison between 4 and 22 hours after treatment and
baseline. Significant values are highlighted and asterisked.
doi:10.1371/journal.pone.0012111.t001
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intensities the b- and a-waves were reduced in amplitude, reaching
a significant only in group 1. The b/a-ratio was slightly and
unsignificantly elevated in both treated groups after four hours.
Compared to this mild effect on the ERG a- and b-wave the dark
adapted oscillatory potentials (OP) were significantly reduced in
amplitude and showed significantly altered peak times in group 1
after 4 hours and in group 2 after 22 hours (Figure 5, Table 5).
Photopic ERG
All photopic ERG responses showed a dose-dependent
amplitude reduction in the treated groups (Figure 5, Table 6).
Significant reductions occured in both treated groups after 4 hours
and in group 2 even after 22 hours. Peak times were also reduced
with the difference reaching a significant level only as to the cone
flicker answer in group 1 after 4 hours.
On-OFF ERG
In group 1 the recordings of only 4 of 6 probands were
considered due to unrecognizable OFF-answers in 2 probands.
The amplitude of the ON-response virtually showed a dose-
dependent increment in both treated groups without reaching a
significant level (Figure 6, Table 7). Peak times of the OFF-
response were significantly reduced in both treated groups after
4 hours (p=0.026 in group 1 and p=0.021 in group 2), the ON-
response was delayed after 22 hours in group 2 (p=0.021). The
OFF-amplitudes were only slighty affected.
Pattern visual evoked potential (pVEP)
Also the pVEP was affected by the administration of ZK 200775
(Figure 7, Table 8). The post-treatment pVEP could be identified
easily due to characteristic morphologic changes. We saw a dose-
dependent peak-time prolongation and amplitude decrease of the
P100 complex. Significant changes were seen in group 2 after four
hours concerning the amplitude for the 1u189 and 17.79 pattern
(p=0.028 and 0.08) and the peak time of the 35.49 pattern
(p=0.038). Surprisingly, there was a peak time reduction for the
check size 17.79 after 4 and 22 hours (p=0.032 and 0.044) in the
control group.
Discussion
ZK 200775 is a glutamate antagonist at the AMPA receptor and
was tested in clinical trials for its neuroprotective effects in cerebral
ischemia. Probands receiving ZK 200775 constantly reported an
alteration of their visual perception. This clinical trial offered the
opportunity to objectify the impact of an AMPA receptor blockade
on the visual system by psychophysical and electrophysiological
means in vivo.
The antagonization of AMPA receptors by ZK200775 led to
alterations of color and dark vision, visual acuity, cone ERG
Table 2. Lanthony Panel D-15 test of color vision.
Group Comparison P-value
Low dose (Group 1) +4 hours vs. baseline 0.011*
+22 hours vs. baseline 0.252
High dose (Group 2) +4 hours vs. baseline 0.001*
+22 hours vs. baseline 0.953
Control group +4 hours vs. baseline 0.905
+22 hours vs. baseline 0.908
P-Values for the comparison between 4 and 22 hours after treatment and
baseline. Significant values are highlighted and asterisked.
doi:10.1371/journal.pone.0012111.t002
Figure 3. Rod threshold. Time course of mean rod threshold +/2 2*
standard deviation for both eyes of all probands. Significant changes
(marked with an asterisk) compared to baseline occured in both treated
groups after 4 hours and also after 22 hours in group 2.
doi:10.1371/journal.pone.0012111.g003
Figure 2. Lanthony Panel D-15 test of color vision. Time course
of error score +/2 2 * standard deviation. Mean values for 6 subjects of
each group. A significant deterioration compared to baseline was
observed in both treated groups immediately after treatment
(asterisked bars).
doi:10.1371/journal.pone.0012111.g002
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ERG. ZK 200775 did not alter eye morphology, functioning of the
extraocular muscles, binocular vision, visual fields or the pupil.
All subjective and objective symptoms found in this study which
could be correlated to the administration of the AMPA antagonist
ZK 200775 are most likely reversible. All parameters that were
altered immediately after administration returned to the normal
range or showed a strong tendency to this after 22 hours.
Most of our psychophysical and electrophysiologic findings are
consistent with the localization of AMPA receptors in the retinal
layers as it was reported by previous experimental research. There
are many indications that AMPA-antagonists compromise the
glutamate action of the middle and inner retina to a larger extent
than the function of outer retinal layers. The alterations of
the flash ERG were subtle and the components representing
photoreceptor function (flash ERG a-wave) were only mildly
reduced. On the other hand, ERG OFF-response and the OPs, all
representing more interior retinal function, were reduced more
markedly in the treated groups.
Our results especially hint at the affection of horizontal and
amacrine cell function. It is known that both cell types play a role
in color vision as well as in the integration of luminance detection.
A functional defect of these cells may therefore lead to a
deterioration of color vision as well as to a reduction of dark
vision. The altered OPs can be regarded as the electrophysiologic
correlate of the impaired amacrine cell function.
Table 3. Rod threshold.
Group
Low Dose (Group 1) High Dose (Group 2) Control Group
Mean STD P-value Mean STD P-value Mean STD P-value
Rod threshold at baseline [log] 4.46 0.10 4.25 0.22 4.29 0.25
Rod threshold at 4 hours [log] 3.83 0.30 0.002* 2.88 0.61 0.002* 4.29 0.25 X
Rod threshold at 22 hours [log] 4.42 0.13 0.363 3.46 0.66 0.026* 4.29 0.25 X
Mean values and standard deviation of rod threshold and t-test results for comparison to baseline. Significant values are highlighted and asterisked. T-test of control
group was not possible due to equal mean values at all times.
doi:10.1371/journal.pone.0012111.t003
Figure 4. Mean dark adapted full-field ERG. Recordings for each group and flash strength at baseline (black line) and 4 hours after treatment
(gray line). The effect of ZK200775 was subtle but recognizable. Statistically significant amplitude reduction of the a- and b-wave occured in the low
dose group after 4 hours.
doi:10.1371/journal.pone.0012111.g004
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agreement with earlier findings. Rods connect primarily to ON
bipolar cells, whereas cones connect to ON or OFF bipolar cells.
AMPA receptors mainly participate in the OFF-pathway but are
also said to be expressed by some ON bipolar cells [19,20,21,22].
While rod bipolar cell dysfunction and synaptic failure between
rods and rod bipolar cells and between cones and cone ON bipolar
cells are well known from a couple of retinal disorders (e.g.
congenital stationary night blindness), failure of the cone OFF-
pathway is rare. ZK200775 mildly altered the ON-pathway
(scotopic ERG and dark vision), the main effect could be observed
in the OFF-pathway and postreceptorally (color vision, visual
acuity, cone ERG modalities).
The most conspicuous finding of this study is the deterioration
of color vision as measured by the Panel D-15 test. After infusion
of ZK200775 the error-score increased significantly in both
treated groups being an almost predictable result of the OFF-
pathway blockade.
The preponderance of non-NMDA receptors in the OFF-
pathway also makes an impairment of central visual acuity after a
partial pharmacological blockade very likely. In this study the
treated probands showed an impairment of visual acuity between
one and two lines.
On the other hand we observed an impairment of dark vision of
approximately 1 log unit that would not be primarily expected
from a pure OFF-pathway blockade. Beside the potential effect of
horizontal cell impairment on scotopic vision additional effect can
be hypothesized. However, recent findings from animal experi-
ments questioning the concept of two strictly independent rod and
cone pathways make it well conceivable that an AMPA blockade
influences scotopic vision as seen in our trial:
1. Several authors reported the expression of AMPA receptors
even in ON bipolar cells [19,20,21,22].
2. Concerning the rodent retina, Hack et al. and Tsukamoto et al.
proved the existence of small populations of OFF bipolar cells
that connect to both cones and rods [23,24,25].
3. The rod pathway is directly connected to the cone pathway via
gap-junctions between cone and rod photoreceptors. There-
fore, the cone OFF bipolar cells also recieve input from rods
[23,24,26,27,25,28].
Concerning the dark adapted full-field ERG, ZK 200775
decreased both the a- and b-wave. At high stimulus intensities
amplitudeswerereducedtoagreaterextentthanatsmallintensities.
The b/a-ratio was slightly elevated in both treated groups four
hours after administration without reaching a significant level.
The b-wave of the dark-adapted ERG is generated mainly by
the rod bipolar cells, the a-wave appears at higher stimulus
intensities and reflects the activity of the rods. Again, as to dark
vision, the small influence on the dark-adapted ERG can be
explained with the minor part AMPA receptors are assumed to
play in the ON-pathway and therefore in scotopic vision. The
dependance between stimulus intensity and ERG alteration can be
explained by the increasing influence of the cones on the ERG
morphology at brighter flashes [29].
In the ON-OFF-ERG flashes of longer duration are used to
separate the activities of both pathways. The ON-answer consists of
the a- and b-wave. The difference to the scotopic ERG is that the
photopicERG b-waveresults from opposing field potentials not only
generated by depolarizing (ON) but also by hyperpolarizing (OFF)
bipolar and horizontal cells as well as third-order neurons [30,31].
Sieving et al. established a ‘‘push-pull model’ of these cell types [32].
Figure 5. Mean cone-ERG. Recordings of each group for baseline (thin line) and 4 hours after treatment (thick line). An almost dose-dependent
amplitude decrease can be seen in all cone-ERG modalities. Significant increments (+) and decrements (2) of the deflections as compared to baseline
are marked in the according graphs (PT=peak time, amp=amplitude).
doi:10.1371/journal.pone.0012111.g005
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ment which corresponds to the results of Sieving et al. and
probably reflects the fading influence of opposing third order
OFF-neurons being blocked by ZK 200775.
TheOFF-answer(ord-wave)appearsafter stimuluscessation and
can be separated from the b-wave only if the stimulus is long
enough. It is said to be generated in OFF-bipolar cells. The OFF-
amplitudes we measured were almost unaffected by the drug but
surprisingly OFF-peaktimes were shortened significantly. These are
paradoxical findings that defy explanation with the hitherto existing
data. Earlier research using DNQX to selectively block AMPA and
KAGluRsevenshoweda reversed polarityof the OFF-answer[31].
The rod-response to flashing stimuli is too slow to allow a
stimulation of rods by flickering light at 30 Hz. Therefore the
flicker-ERG is a parameter of cone function. In the treated groups,
the cone-mediated answers showed reduced amplitudes (flicker-
response and red light and single-flash answer) and delayed peak
times (flicker-response). Yet, all cone answers were still recogniz-
able. This again proves the influence of ZK200775 on the OFF-
pathway but argues against its complete blockade.
The VEP is a parameter for the integrity of the entire visual
pathway [29]. The reduction of the pVEP amplitudes may be
explained by the influence of the drug on the ganglion cell function or
even on the middle and outer retinal layers. Moreover, we recorded
significantly prolonged implicit times of the P100 complex which is
commonly regarded as a marker of impaired nerval conduction like
in optic nerve inflammation. We assume that upstream retinal
alterations have led to a secondary peak time prolongation. The peak
time reduction in the control group after treatment supposedly arises
from the principal variability of this electrophysiologic method.
Our results maintain that AMPA receptors predominate in
the OFF-pathway and play a minor role in the ON-pathway.
Nevertheless, the interdependence of both pathways becomes
apparent. Surprising findings were the partial preservation of visual
acuity, deteriorated dark vision, the persistent OFF-answer with it’s
s h o r t e n e dp e a kt i m ea n dt h ep e a kt i m ed e l a yo ft h ep V E P .
Figure 7. Mean pattern visual evoked potential. Recordings for each group and check size. Stimulation of the left eye with natural pupil. Thin
lines: baseline recordings, thick lines: recordings 4 hours after treatment. This figure shows a virtually dose-dependent amplitude decrease and peak
time prolongation. Significant increments (+) and decrements (2) of the deflections as compared to baseline are marked in the according graphs
(PT=peak time, amp=amplitude).
doi:10.1371/journal.pone.0012111.g007
Figure 6. Mean ON-OFF-ERG. Recordings of each group for baseline
(thin line) and 4 hours after treatment (thick line). In group 1 the
recordings of only 4 of 6 probands were considered due to
unrecognizable OFF-answers in 2 probands. An increase of on-answer
amplitude in both treated groups seems obvious but was statistically
not significant. However, there was a significant reduction of OFF-
answer peak time (PT) in both treated groups 4 hours after treatment.
doi:10.1371/journal.pone.0012111.g006
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definition of the role of AMPA receptors in the human retina they
render some information concerning the relevance of glutamate
for vision and for the components of the electroretinogram.
Whereas the latter could also be studied in animals, this study
offered a unique chance to elucidate the impact of AMPA on the
psychophysically examined vision in humans.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol S1.
This clinical trial was approved by the ‘‘Ethikkommission der
Berliner Aerztekammer’’ (Ethics Committee of the Berlin Medical
Association) and was conducted according to the Declaration of
Helsinki. All probands gave written informed consent to
participate in the study.
18 healthy probands were recruited for this study. Recruitment
was done vı ´a random selection of probands from the central
Schering database on the basis of inclusion and exclusion criteria
(Table S6). Recruitment period lasted from Februar to July 1997.
All probands were of male sex, the mean age was 61 years (57 to
69 years). None of the probands participated in other phase I trials
concerning ZK200775.
Table 4. Scotopic ERG.
Group
Low Dose High Dose Control Group
(Group 1) (Group 2)
Mean STD P-value Mean STD P-value Mean STD P-value
BASELINE Amplitude of the maximum a-wave [mV] 253.58 61.52 284.83 37.55 248.34 70.46
Peak time of the maximum a-wave [ms] 14.00 0.63 14.83 0.75 14.17 0.75
Amplitude of the maximum b-wave [mV] 414.96 119.75 451.61 58.97 392.52 72.56
Peak time of the maximum b-wave [ms] 42.33 2.50 42.67 3.01 43.5 4.32
b/a-ratio 1.63 0.21 1.59 0.14 1.63 0.33
4 HOURS Amplitude of the maximum a-wave [mV] 196.48 73.40 0.03* 247.99 70.60 0.293 253.64 66.20 0.77
Peak time of the maximum a-wave [ms] 14.17 0.41 0.611 15.33 0.52 0.076 14.17 0.75 1.00
Amplitude of the maximum b-wave [mV] 339.90 113.63 0.008* 408.12 111.78 0.407 369.17 63.45 0.298
Peak time of the maximum b-wave [ms] 44.17 3.19 0.33 45.83 6.40 0.195 43.67 3.01 0.842
b/a-ratio 1.77 0.29 0.076 1.67 0.26 0.305 1.50 0.22 0.225
22 HOURS Amplitude of the maximum a-wave [mV] 257.57 67.54 0.855 246.74 55.92 0.212 249.19 48.77 0.959
Peak time of the maximum a-wave [ms] 14.17 0.75 0.695 14.67 0.52 0.611 14.00 0.89 0.695
Amplitude of the maximum b-wave [mV] 396.97 106.19 0.365 404.89 66.81 0.223 375.95 40.77 0.539
Peak time of the maximum b-wave [ms] 42.00 2.68 0.809 41.67 3.56 0.536 43.50 3.56 1.00
b/a-ratio 1.56 0.24 0.543 1.67 0.25 0.338 1.54 0.24 0.342
Mean data of the scotopic combined rod and cone a- and b-wave amplitude and peak time and of b/a-ratio. Significant changes compared to baseline (t-test) occured
in the low-dose group and are highlighted and asterisked. Note that mean values were calculated from the individual recordings taken from each proband and may
thus differ from the values depicted in Figure 4.
doi:10.1371/journal.pone.0012111.t004
Table 5. Oscillatory potentials.
Group
Low Dose (Group 1) High Dose (Group 2) Control Group
Mean STD P-value Mean STD P-value Mean STD P-value
OP2 amplitude at baseline [mikrovolt] 53.8 14.2 46.7 13.7 44.6 15.4
OP2 peak time at baseline [ms] 22.8 0.31 22.9 0.33 22.5 0.45
OP2 amplitude at 4 hours [mikrovolt] 30.4 9.34 0.01* 19.4 8.17 0.06 41.8 16.3 0.425
OP2 peak time at 4 hours [ms] 23.6 0.62 0.025* 19.8 3.39 0.061 22.4 0.49 0.363
OP2 amplitude at 22 hours [mikrovolt] 48 15 0.243 26.3 13.6 0.04* 41.4 12.9 0.343
OP2 peak time at 22 hours [ms] 23 0.82 0.465 24.3 0.96 0.013* 22.6 0.54 0.611
Mean values and standard deviation of amplitude and peak time and p-values for the comparison to baseline. Significant changes compared to baseline (t-test) are
highlighted and asterisked. Note that mean values were calculated from the individual recordings taken from each proband and may thus differ from the values
depicted in Figure 5.
doi:10.1371/journal.pone.0012111.t005
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logical examination screened out any relevant medical or vision
disorders. If the proband was included in the study this checkup
also served as baseline examination and encompassed:
N Medical and opthalmological history
N Visual acuity
N Stereopsis (Titmus-test)
N Eye position, motility, pupillary reaction
Table 6. Cone-ERG.
Group
Low Dose (Group 1) High Dose (Group 2) Control Group
Mean STD P-value Mean STD P-value Mean STD P-value
BASELINE Cone single flash answer amplitude [mV] 155.3 44.2 149.2 29.8 120.3 24.3
Cone single flash answer peak time [ms] 32.2 1.2 31.2 1.3 31 1
Cone red light answer amplitude [mV] 95.39 17.4 91.88 31.7 77.41 17.2
Cone red light answer peak time [ms] 28.14 0.98 28.3 0.63 27.9 0.88
Cone flicker answer amplitude [mV] 135.3 35.8 137.6 29.1 122.1 31
Cone flicker answer peak time [ms] 27.24 1.4 26.52 1.24 26.64 1.02
+4 HOURS Cone single flash answer amplitude [mV] 106.3 40.1 0.003* 76.94 25.4 0.001* 114.2 20.4 0.456
Cone single flash answer peak time [ms] 31.3 3.32 0.605 30 2.98 0.328 31.2 1.05 0.363
Cone red light answer amplitude [mV] 67.5 24.5 0.038* 40.78 10.8 0.005* 74.73 13.9 0.744
Cone red light answer peak time [ms] 28.2 1.24 0.945 26.6 3.23 0.233 27.9 0.59 1
Cone flicker answer amplitude [mV] 108.1 39.3 0.108 78.49 15.9 0.000* 111.2 15.1 0.311
Cone flicker answer peak time [ms] 30.12 1.73 0.002* 26.16 1.18 0.624 26.52 0.96 0.363
+22 HOURS Cone single flash answer amplitude [mV] 136.1 35.6 0.233 108.1 22.6 0.002* 113.9 14.4 0.562
Cone single flash answer peak time [ms] 31.6 1.26 0.497 30.7 1.85 0.383 31.4 0.82 0.235
Cone red light answer amplitude [mV] 80.51 15.1 0.123 54.81 13.3 0.012* 80.91 19.8 0.638
Cone red light answer peak time [ms] 27.8 1.55 0.419 27.9 0.7 0.444 28 0.54 0.809
Cone flicker answer amplitude [mV] 122.2 32.8 0.456 102 25.4 0.021* 114.2 23 0.503
Cone flicker answer peak time [ms] 27.24 1.06 1 27.36 1.2 0.058 26.52 0.96 0.363
Mean values and standard deviation of amplitude and peak time and p-values for the comparison to baseline. Significant changes (t-test) are highlighted and asterisked.
Note that mean values were calculated from the individual recordings taken from each proband and may thus differ from the values depicted in Figure 5.
doi:10.1371/journal.pone.0012111.t006
Table 7. ON-OFF-ERG.
Group
Low Dose (Group 1) High Dose (Group 2) Control Group
Mean STD P-value Mean STD P-value Mean STD P-value
BASELINE Amplitude of the on answer [mikrovolt] 49.5 22.9 59.71 25.6 39.66 13.9
Peak time of the on answer [ms] 46.8 3.6 46.8 2.85 47.07 3.93
Amplitude of the off answer [mikrovolt] 14.4 7.08 14.6 7.5 9.86 3.34
Peak time of the off answer [ms] 226 1.46 225.3 1.8 224.8 1.75
+4 HOURS Amplitude of the on answer [mikrovolt] 59.1 38.2 0.322 70.77 20.2 0.211 42.59 12 0.552
Peak time of the on answer [ms] 46.5 4.06 0.75 49.29 6.05 0.215 46.27 3.66 0.229
Amplitude of the off answer [mikrovolt] 6.55 4.18 0.223 14.66 9.89 0.986 10.42 3.04 0.771
Peak time of the off answer [ms] 219 2.56 0.026* 221.3 1.87 0.021* 225.6 1.96 0.348
+22 HOURS Amplitude of the on answer [mikrovolt] 46 16.1 0.531 56.34 33 0.579 47.36 21.7 0.453
Peak time of the on answer [ms] 44.7 3.41 0.199 45.07 2.36 0.021* 45.73 4.19 0.129
Amplitude of the off answer [mikrovolt] 8.24 3.05 0.11 10.99 3.59 0.324 12.96 4.96 0.151
Peak time of the off answer [ms] 225 3.22 0.432 224.1 1.15 0.235 225.3 1.57 0.484
Mean values, standard deviation of amplitude and peak time and p-values for comparison to baseline. Significant changes are highlighted and asterisked. Note that
mean values were calculated from the individual recordings taken from each proband and may thus differ from the values depicted in Figure 6.
doi:10.1371/journal.pone.0012111.t007
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# To calculate the error score of the Panel test the differences
of the values of every two connected Panels were calculated
and added (sums up to 15 for an entirely correct test). Then,
15 was subtracted from the sum (as the error score for a
correct test must be 0).
N Central visual field (Amsler grid)
N Applanation tonometry (Goldmann)
N Slit lamp examination of the anterior segment
N Funduscopy.
Randomization was executed via stratification. A sequential
(‘dose escalation’) strategy beginning with the low-dose stratum
and continuing to the high-dose stratum was planned. There were
two strata, one for each dosage group (0.03 an 0.75 mg/kg/h). In
every stratum there were two possible treatments: ZK200775 or
placebo. The verum-group included 6 participants, the placebo
group 3 participants per dosage group. In total, 18 participants
were allocated to the treatments with a ratio of 2:1 (12 ZK200775
[6 with a dosage of 0.03 mg/kg/h and 6 with a dosage of
0.75 mg/kg/h], 6 Placebo [0.9% sodium chloride solution], see
Figure 8).
All participants as well as all persons involved in drug
application and examination were blinded from drug or placebo
assignment inside the group. There was no blinding between
strata. An independent team with access to a randomization list
prepared the investigational product and the infusion system on
the morning of treatment. Another randomization list was
deposited in the trial master file. Emergency envelopes were
stored in the Schering Institute for Clinical Pharmacology and
were also available for the investigator.
There were no explicit outcome measures. The aim of the study
was to quantifiy the ophthalmologic effects of ZK200775 by
adequate examinations.
On the day of drug administration an additional ophthalmological
examination was performed before, immediately after (4 hours after
treatment onset) and 22 hours after onset of drug administration.
These examinations comprised the points mentioned above except
history and tonometry. Additionally, the rod absolute threshold was
tested in the right eye with dilated pupil with a Hartinger
adaptometer (Carl Zeiss, Jena) after 30 minutes of dark adaptation.
Electrophysiologic examinations were also performed before,
immediately after and 22 hours after drug administration. For the
full-field ERG the pupil of the right eye was dilated with
tropicamide. For the remaining examinations the pupil of the left
eye remained neutral. For electrophysiological recordings a
Nicolet BravoH unit was employed (Nicolet Germany, Hoech-
berg). Thread conjunctival electrodes were used for electroreti-
nography. All recordings were made according to the Standard of
the International Society of Clinical Electrophysiology of Vision
(ISCEV).
Full-field electroretinogram (ERG)
Four scotopic responses with increasing stimulus intensity
following dark adaptation.
Table 8. PVEP.
Group
Low Dose High Dose Control Group
(Group 1) (Group 2)
Mean STD P-value Mean STD P-value Mean STD P-value
BASELINE 1u189 amplitude [mV] 7,11 2,01 9,38 4,47 7,44 2,68
1u189 peak time [ms] 107,83 6,31 109,67 6,35 115,00 6,20
35.49 amplitude [mV] 7,74 1,16 9,15 5,17 7,43 3,51
35.49 peak time [ms] 109,83 5,34 112,00 5,44 115,83 6,15
17.79 amplitude [mV] 8,35 3,07 10,04 5,16 7,99 2,79
17.79 peak time [ms] 114,50 5,05 115,83 5,31 121,33 6,53
+4 HOURS 1u189 amplitude [mV] 6,24 1,11 0,354 7,12 4,09 0,028* 6,46 2,94 0,361
1u189 peak time [ms] 111,67 9,61 0,112 122,33 17,99 0,064 115,00 7,40 1
35.49 amplitude [mV] 6,53 1,42 0,11 7,30 3,17 0,194 7,43 3,85 0,997
35.49 peak time [ms] 112,33 9,33 0,273 123,67 13,29 0,038* 115,33 9,56 0,843
17.79 amplitude [mV] 7,17 3,80 0,58 6,66 3,87 0,08* 8,33 3,10 0,753
17.79 peak time [ms] 118,17 8,04 0,212 126,00 13,43 0,061 118,83 5,95 0,032*
+22 HOURS 1u189 amplitude [mV] 6,42 1,51 0,495 9,25 4,54 0,465 6,95 2,86 0,529
1u189 peak time [ms] 112,50 6,60 0,158 110,20 4,32 0,17 117,83 7,44 0,186
35.49 amplitude [mV]] 7,61 2,56 0,915 10,43 5,35 0,657 7,79 4,31 0,745
35.49 peak time [ms] 110,17 8,98 0,868 109,60 5,59 0,871 116,67 5,32 0,601
17.79 amplitude [mV] 9,71 3,98 0,313 10,99 6,85 0,292 8,06 4,05 0,961
17.79 peak time [ms] 113,67 5,01 0,652 122,00 4,82 0,059 119,43 5,53 0,044*
Mean values, standard deviation and p-values for amplitude and peak time of P100. Significant changes compared to baseline (t-test) are highlighted and asterisked.
Note that mean values were calculated from the individual recordings taken from each proband and may thus differ from the values depicted in Figure 7.
doi:10.1371/journal.pone.0012111.t008
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Initial dark adaptation. High pass filter: 100 Hz.
Cone-ERG
Initially ten minutes of light adaptation (30 cdm
22). Recording
of single-flash cone response, cone red light answer and response
to 30 Hz flicker.
ON-OFF ERG
Stimulation with red flashes of a duration of 200 ms delivered
through light emitting diodes following light adaptation.
Pattern-reversal visual evoked potential (pVEP)
Check size of 17.79, 35.49 and 1,18u at 3 reversals per second.
Stimulation of the left eye with the natural pupil.
Mean amplitude and peak time was calculated for all tested indivi-
duals at each measurement (before administration, immediately after
treatment [4:00 hours] and 22:00 hours after the onset of treatment).
Post-treatment values at 4 and 22 hours (visual acuity, error
score of the Panel test, rod threshold, peak time and amplitude of
the electrophysiologic recordings) were compared to baseline
measurements using the t-test. P-values ,0.05 were regarded as
statistically significant.
Figure 8. Consort flow chart.
doi:10.1371/journal.pone.0012111.g008
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Checklist S1 Consort Checklist
Found at: doi:10.1371/journal.pone.0012111.s001 (0.19 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0012111.s002 (108.83 MB
PDF)
Figure S1 Glutamate receptor subtypes.
Found at: doi:10.1371/journal.pone.0012111.s003 (0.02 MB TIF)
Table S1 Ionotropic glutamate receptor expression in retinal
neurons and retinal layers. Immunocytochemistry, in situ
hybridization and polymerase chain reaction. Based on Webvi-
sion, completed by the authors (http://webvision.med.utah.edu,
author: Vikki P. Connaughton). Some papers could not be
considered in this survey.
Found at: doi:10.1371/journal.pone.0012111.s004 (0.15 MB
DOC)
Table S2 Eye position. Data for both eyes for each group before
infusion and 4 and 22 hours after infusion of ZK 200775. No
significant changes occurred.
Found at: doi:10.1371/journal.pone.0012111.s005 (0.05 MB
DOC)
Table S3 Eye Motility. Data for both eyes and each group
before infusion and 4 and 22 hours after infusion of ZK 200775.
No significant changes occurred.
Found at: doi:10.1371/journal.pone.0012111.s006 (0.05 MB
DOC)
Table S4 Pupil light response. Data of the left eye for each
group before infusion and 4 and 22 hours after infusion of ZK
200775. No significant changes occurred.
Found at: doi:10.1371/journal.pone.0012111.s007 (0.03 MB
DOC)
Table S5 Amsler Card examination. Data of the left eye for each
group before infusion and 4 and 22 hours after infusion of ZK
200775. No significant changes occurred.
Found at: doi:10.1371/journal.pone.0012111.s008 (0.04 MB
DOC)
Table S6 Inclusion and exclusion criteria.
Found at: doi:10.1371/journal.pone.0012111.s009 (0.04 MB
DOC)
Author Contributions
Conceived and designed the experiments: TS KR. Performed the
experiments: KR. Analyzed the data: RB. Contributed reagents/
materials/analysis tools: TS. Wrote the paper: RB KR.
References
1. Matsui K, Hosoi N, Tachibana M (1998) Excitatory synaptic transmission in the
inner retina: paired recordings of bipolar cells and neurons of the ganglion cell
layer. J Neurosci 18: 4500–4510.
2. Thoreson WB, Witkovsky P (1999) Glutamate receptors and circuits in the
vertebrate retina. Prog Retin Eye Res 18: 765–810.
3. Brandstatter JH (2002) Glutamate receptors in the retina: the molecular
substrate for visual signal processing. Curr Eye Res 25: 327–331.
4. Grunder T, Kohler K, Guenther E (2000) Distribution and developmental
regulation of AMPA receptor subunit proteins in rat retina. Invest Ophthalmol
Vis Sci 41: 3600–3606.
5. Zhang C, Hammassaki-Britto DE, Britto LR, Duvoisin RM (1996) Expression of
glutamate receptor subunit genes during development of the mouse retina.
Neuroreport 8: 335–340.
6. Atlante A, Calissano P, Bobba A, Giannattasio S, Marra E, et al. (2001)
Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett 497:
1–5.
7. Choi DW (1992) Excitotoxic cell death. J Neurobiol 23: 1261–1276.
8. Brandstatter JH, Koulen P, Wassle H (1998) Diversity of glutamate receptors in
the mammalian retina. Vision Res 38: 1385–1397.
9. Qin P, Pourcho RG (1996) Distribution of AMPA-selective glutamate receptor
subunits in the cat retina. Brain Res 710: 303–307.
10. Peng YW, Blackstone CD, Huganir RL, Yau KW (1995) Distribution of
glutamate receptor subtypes in the vertebrate retina. Neuroscience 66: 483–497.
11. Hughes TE (1997) Are there ionotropic glutamate receptors on the rod bipolar
cell of the mouse retina? Vis Neurosci 14: 103–109.
12. Connaughton V (2003) Webvision: Glutamate and glutamate receptor subtypes
in the vertebrate retina. http://webvision med utah edu/.
13. (1999) Unpublished Schering Research Report AG99. Explorative investigation
of safety, tolerability, pharmacodynamics and pharmacokinetics after infusions
of ZK 200775 with increasing doses in older subjects.
14. (1999) Unpublished Schering Research Report AO12. Exploratory investigation
of safety, tolerability, and steady-state kinetics after a 24-hour infusion with ZK
200775 in 55- to 65-year-old male volunteers when administered as a loading
and subsequent maintenance dose.
15. (1999) Unpublished Schering Research Report AR35.The influence of impaired
kidney function on the pharmacokinetics of ZK 200775 after a 4-hour infusion
of 10 mg/hour ZK 200775 in male volunteers in the age groups 40 to 59 and 60
to 80 in an open-labeled trial design.
16. Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, et al. (2002) AMPA
antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell
toxicity detected by monitoring of S-100B serum levels. Stroke 33: 2813–2818.
17. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, et al. (1998)
ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuropro-
tection in stroke and trauma. Proc Natl Acad Sci U S A 95: 10960–10965.
18. Walters MR, Kaste M, Lees KR, Diener HC, Hommel M, et al. (2005) The
AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-
blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc
Dis 20: 304–309.
19. Calkins DJ (2005) Localization of ionotropic glutamate receptors to invaginating
dendrites at the cone synapse in primate retina. Vis Neurosci 22: 469–477.
20. Harvey DM, Calkins DJ (2002) Localization of kainate receptors to the
presynaptic active zone of the rod photoreceptor in primate retina. Vis Neurosci
19: 681–692.
21. Kamphuis W, Klooster J, Dijk F (2003) Expression of AMPA-type glutamate
receptor subunit (GluR2) in ON-bipolar neurons in the rat retina. J Comp
Neurol 455: 172–186.
22. Morigiwa K, Vardi N (1999) Differential expression of ionotropic glutamate
receptor subunits in the outer retina. J Comp Neurol 405: 173–184.
23. Hack I, Peichl L, Brandstatter JH (1999) An alternative pathway for rod signals
in the rodent retina: rod photoreceptors, cone bipolar cells, and the localization
of glutamate receptors. Proc Natl Acad Sci U S A 96: 14130–14135.
24. Hack I, Frech M, Dick O, Peichl L, Brandstatter JH (2001) Heterogeneous
distribution of AMPA glutamate receptor subunits at the photoreceptor synapses
of rodent retina. Eur J Neurosci 13: 15–24.
25. Tsukamoto Y, Morigiwa K, Ueda M, Sterling P (2001) Microcircuits for night
vision in mouse retina. J Neurosci 21: 8616–8623.
26. Hornstein EP, Verweij J, Li PH, Schnapf JL (2005) Gap-junctional coupling and
absolute sensitivity of photoreceptors in macaque retina. J Neurosci 25:
11201–11209.
27. Lee EJ, Han JW, Kim HJ, Kim IB, Lee MY, et al. (2003) The
immunocytochemical localization of connexin 36 at rod and cone gap junctions
in the guinea pig retina. Eur J Neurosci 18: 2925–2934.
28. Zhang J, Wu SM (2004) Connexin35/36 gap junction proteins are expressed in
photoreceptors of the tiger salamander retina. J Comp Neurol 470: 1–12.
29. Bach M, Kellner U (2000) [Electrophysiological diagnosis in ophthalmology].
Ophthalmologe 97: 898–920.
30. Dong CJ, Hare WA (2000) Contribution to the kinetics and amplitude of the
electroretinogram b-wave by third-order retinal neurons in the rabbit retina.
Vision Res 40: 579–589.
31. Awatramani G, Wang J, Slaughter MM (2001) Amacrine and ganglion cell
contributions to the electroretinogram in amphibian retina. Vis Neurosci 18:
147–156.
32. Sieving PA, Murayama K, Naarendorp F (1994) Push-pull model of the primate
photopic electroretinogram: a role for hyperpolarizing neurons in shaping the b-
wave. Vis Neurosci 11: 519–532.
Effects of ZK 200775 on Vision
PLoS ONE | www.plosone.org 11 August 2010 | Volume 5 | Issue 8 | e12111